[Daily clinical practice: Biological testing in osteoporosis]

Area of Science:

• Endocrinology
• Metabolic Bone Disease

Context:

• Osteoporosis diagnosis relies on bone density scans, not biological tests.
• Biological testing plays a supportive role in managing osteoporosis.
• Current guidelines lack consensus on specific biochemical parameters for osteoporosis evaluation.

Purpose:

• To outline the utility of biological testing in identifying secondary causes of low bone mass and monitoring osteoporosis treatment efficacy.
• To highlight essential biochemical tests for evaluating calcium/phosphorus metabolism and ruling out conditions like myeloma.
• To emphasize the importance of tracking bone turnover markers for assessing osteoporosis treatment response.

Summary:

• Biological tests help detect secondary osteoporosis causes, such as primary hyperparathyroidism and vitamin D deficiency, by assessing calcium, phosphate, PTH, and 25 hydroxy-vitamin D levels.
• Experts recommend ruling out malignancy, especially myeloma.
• Monitoring bone turnover markers, like CTX (C-terminal telopeptide of type I collagen), over 3-6 months indicates treatment efficacy, with a >30% decrease signifying reduced bone resorption.

Impact:

• Provides a framework for cost-effective biological evaluation in osteoporosis management.
• Enhances clinical decision-making by clarifying the role of biochemical testing.
• Facilitates personalized treatment monitoring for osteoporosis patients, improving therapeutic outcomes.